The thing to understand about Anatome as a business is that its installed base is not devices, It is people, roughly two hundred and ten million of them across the licensed markets, and the company’s churn rate is therefore mortality, which is the most predictable number in any model anyone has ever built. Analysts who came up covering software spent the first years of this decade trying to fit the usual frameworks to it and mostly gave up. There is no competitive switching in a market where switching requires surgery.
Share is somewhere around ninety-one per cent by units and higher by revenue, since the two remaining manufacturers of any size sell into the sectors where subscription tiers are thinnest. Anneke Roos has been chief executive since 2043 and has never, so far as I can find in any transcript, used the word monopoly in public. She prefers to describe Anatome as infrastructure, which is both a defensible characterisation and an unusually candid one, given what infrastructure is generally permitted to charge.
The structural feature that the coverage keeps missing sits one level down, in the plumbing between the dividend and the tier. Performance tiers are billed against the blended wage, and for municipal-tier users the blended wage is mostly dividend. The dividend is funded by automation levies. So a levy raised on the automation of human labour is collected by the state, distributed to citizens, and remitted within the month to a private firm in Basel in exchange for permission to move at a speed the hardware is already capable of. I have run the flows twice because I did not believe them the first time. On the numbers I can see, something between eleven and fourteen per cent of the municipal dividend in the northern sectors arrives at Anatome, which makes the company the largest single beneficiary of a public transfer designed to compensate people for the loss of their work.
Which brings me to the reclassification order, and to a piece of arithmetic that Celestine’s dispatch from Singapore did not have space to run and that I suspect will not be dwelt on in Basel either. Forty million people whose limbs were carried by restorative coverage move, from January, onto tier subscriptions they pay themselves. Nothing about the hardware changes. Nothing about the service changes. A cohort previously billed to public schedules at negotiated rates simply becomes a retail cohort at retail rates, so that if the take-up assumptions in the sell-side notes are anywhere near right, that single regulatory instrument is worth more to Anatome than the entire Series Nine launch was.
I want to be careful here, because the obvious inference is that the company procured the order, and I have found nothing to support that and would be surprised if anything existed. The regulators appear to have reasoned their way to it independently and on medical logic. It happens to be the most valuable thing that has been done for this company in a decade, and both of those statements can be true at once, as they tend to be when a fortune is made quickly.
The one genuine risk to the multiple is the disclosure motion. If the tribunal orders the conformance firmware into evidence, the immediate consequence is not liability but something considerably worse for a company valued as infrastructure, which is auditability. Once an envelope can be read it can be replicated, which in turn means that a limb whose behaviour is independently verifiable becomes serviceable by somebody other than its manufacturer. The desk I trust most is pricing disclosure at a little better than one in three, and has been marking the position down since Vieiro’s testimony was scheduled.
There is already a visible second-order effect, which is that liability cover for Conductors in the prosthetics certification class has repriced by a factor of about six since April. Several underwriters have withdrawn from the line entirely. The practical result is that the pool of people willing to put a signature at the bottom of a firmware release is shrinking at exactly the moment the company most needs signatures, which has forced Anatome into raising Conductor pay, the first honest price signal this industry has produced in years.
What that price says, if you read it plainly, is that the company now knows what it costs to buy a person’s name. It is a little over four times what it cost in the spring, and it is still cheaper than opening the code.